Human Inositol Hexakisphosphate Kinase 2 (IP6K2) activation kit by CRISPRa

CAT#: GA109811

IP6K2 CRISPRa kit - CRISPR gene activation of human inositol hexakisphosphate kinase 2



  See Other Versions

CNY 12255.00


货期*
4周

规格
    • 1 kit

Product images

推荐一起购买 (3)
IP6K2 mouse monoclonal antibody,clone OTI1F12
    • 100 ul

CNY 1999.00
CNY 2700.00


IP6K2 (Myc-DDK-tagged)-Human inositol hexakisphosphate kinase 2 (IP6K2), transcript variant 1
    • 10 ug

CNY 3656.00
CNY 3990.00


IP6K2 mouse monoclonal antibody,clone OTI1F12
    • 30 ul

CNY 800.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol IP6K2
Locus ID 51447
Kit Components

GA109811G1, Inositol Hexakisphosphate Kinase 2 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA109811G2, Inositol Hexakisphosphate Kinase 2 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA109811G3, Inositol Hexakisphosphate Kinase 2 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Reference Data
RefSeq NM_001005909, NM_001005910, NM_001005911, NM_001005912, NM_001005913, NM_001146178, NM_001146179, NM_001190316, NM_001190317, NM_016291, NR_027437, NR_027438
Synonyms IHPK2; PIUS
Summary This gene encodes a protein that belongs to the inositol phosphokinase (IPK) family. This protein is likely responsible for the conversion of inositol hexakisphosphate (InsP6) to diphosphoinositol pentakisphosphate (InsP7/PP-InsP5). It may also convert 1,3,4,5,6-pentakisphosphate (InsP5) to PP-InsP4 and affect the growth suppressive and apoptotic activities of interferon-beta in some ovarian cancers. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...